A new conceptual framework may help clinicians better diagnose and treat children with inflammatory symptoms that resemble Behçet's disease but do not meet classic diagnostic criteria. Researchers from Peking Union Medical College Hospital in Beijing have published a review article in the World Journal of Pediatrics (DOI: 10.1007/s12519-026-01035-4) that formally maps out Behçet's spectrum disorders (BSD), a concept first introduced in 2020 to link diverse inflammatory conditions through shared immune pathways.
Behçet's disease (BD) is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Furthermore, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms, yet they are biologically distinct and require different treatments. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering. The BSD framework aims to address these challenges by providing a mechanism-oriented lens for earlier recognition and genetic screening in children with Behçet-like presentations.
The researchers propose a two-tier classification based on genetic and mechanistic evidence. The "core" BSD tier comprises monogenic diseases that directly disrupt NF-κB or JAK-STAT signaling, including HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and show strong convergence on BD-relevant inflammatory circuits. The "peripheral" BSD tier includes polygenic or multifactorial entities such as recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap or indirect pathway engagement but lack a defining monogenic driver.
A major highlight is the identification of NF-κB and JAK-STAT as two central inflammatory hubs that serve as common denominators across the entire spectrum, providing a rational basis for grouping these diverse disorders. The authors also carefully delineate exclusion criteria, distinguishing true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations, thereby sharpening diagnostic boundaries. Importantly, the framework does not replace existing BD criteria but offers a mechanism-oriented approach to prioritize genetic testing in early-onset or atypical pediatric cases, significantly reducing diagnostic odysseys.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL-1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism-based trials.
"We're not saying these are all the same disease—they're not," the authors said. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why." They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
